title: Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
authors.affiliation: Department of Pathology, Delhi State Cancer Institute, Dilshad Garden, Delhi - 95, India. drkiranpreetmalhotra@yahoo.co.in
authors.forename: K P
authors.initials: KP
authors.lastname: Malhotra
authors.forename: C B
authors.initials: CB
authors.lastname: Sharma
authors.forename: J
authors.initials: J
authors.lastname: Jain
authors.forename: R K
authors.initials: RK
authors.lastname: Grover
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl